Globus Medical Earnings: A Post-Merger Report Card on Feb 24

AUDUBON, PA – February 12, 2026 – Globus Medical, Inc. (NYSE:GMED) is set to provide the investment community with its most comprehensive post-merger financial report card to date, as the company will release its fourth quarter and full-year 2025 earnings after the market closes on Tuesday, February 24, 2026. The announcement and subsequent investor call are highly anticipated, as they will offer critical insights into the operational success of the NuVasive integration and the company's trajectory heading into the new year.

Following a year of transformative strategic moves, including the landmark NuVasive merger and the acquisition of Nevro, stakeholders are eager to dissect the full-year numbers. These results will not only illuminate Globus Medical's financial health but also serve as a key bellwether for the broader musculoskeletal device market. The company will host a conference call for investors at 4:30 p.m. Eastern Time on the day of the release to discuss the results in detail.

A Pivotal Year of Integration and Growth

The story of Globus Medical in 2025 was defined by its ambitious integration of NuVasive, which closed in late 2023. The year began with some turbulence, as the first quarter was marked by a slight revenue dip and missed forecasts, attributed by former company leadership to temporary integration-related supply chain disruptions and softness in enabling technology sales. The stock took a hit, and investors watched closely to see if the company could navigate the complexities of combining two industry giants.

However, the narrative shifted dramatically in the subsequent quarters. Globus Medical reported a strong rebound, exceeding analyst expectations for both revenue and earnings in the second and third quarters. Q3 2025 was particularly robust, with worldwide net sales climbing 22.9% year-over-year to $769.0 million and non-GAAP diluted earnings per share (EPS) of $1.18, shattering consensus estimates by over 50%. The company also generated a record free cash flow of $213.9 million in the third quarter, a clear sign of improving operational efficiency.

A key financial milestone was achieved early in the year when Globus Medical paid off the remaining $450 million in debt from the NuVasive merger, returning the company to a debt-free status. This disciplined capital management, combined with the successful integration of another strategic acquisition—spinal cord stimulator company Nevro for $250 million in Q1—bolstered investor confidence. The Nevro business proved accretive to earnings ahead of schedule, contributing nearly $100 million in revenue in the third quarter alone.

Scrutinizing the Numbers: From Guidance to Reality

Investors will be parsing the February 24th report to see how the final numbers align with the company's evolving guidance and preliminary announcements. After a cautious start, Globus Medical repeatedly raised its full-year 2025 outlook. The initial non-GAAP EPS guidance of $3.10 to $3.40 was ultimately revised upward to a range of $3.75 to $3.85 following the strong Q3 performance.

Preliminary unaudited sales figures released in January 2026 have already set a high bar. The company announced it expects to report approximately $823.2 million in sales for the fourth quarter, a 25.2% increase over the prior year's quarter. This would bring full-year 2025 sales to an estimated $2.936 billion, a significant 16.5% increase from 2024 and above the high end of its most recent guidance.

These preliminary results suggest a powerful finish to the year, and analysts have taken note. Zacks Research recently increased its full-year 2025 EPS estimate for the company to $3.77 per share. The upcoming report will confirm the final profitability metrics and shed light on the synergy capture and operating leverage gained from the recent mergers, with the adjusted EBITDA margin having already shown meaningful improvement to 32.8% in Q3.

Performance Across the Portfolio

The strength in 2025 was not isolated to a single division. A deep dive into the preliminary results and prior quarters reveals broad-based demand across Globus Medical's diverse portfolio, a testament to its market position.

• U.S. Spine: This core segment has been a standout performer, demonstrating consistent growth and market share gains throughout the year. After accelerating to 10% growth in Q3, the division reportedly maintained this momentum, with executives noting a continued positive trend into the fourth quarter.

• Orthopedic Trauma: The trauma business delivered its highest quarterly revenue since inception in Q3 2025 with a 17.2% increase, fueled by an expanded product portfolio launched in late 2024. This segment’s performance indicates successful penetration into a competitive market.

• Enabling Technologies: This high-tech segment, which includes robotics and imaging systems, had a challenging start to 2025, with sales declining against tough competition. However, it appears to have staged a dramatic turnaround. Preliminary Q4 results indicate that the division delivered its best quarterly revenue performance to date, suggesting that hospital capital spending may have rebounded or that the company’s sales strategies are gaining significant traction.

Bellwether for the Musculoskeletal Market

Globus Medical's performance does not exist in a vacuum. Its results are often viewed as an indicator of the health of the entire musculoskeletal sector. The strong demand seen across its spine and trauma divisions aligns with positive trends reported by competitors. Zimmer Biomet, for instance, also reported strong Q4 2025 results with revenue up nearly 11%, citing robust demand across its core business lines.

This industry-wide strength suggests that procedural volumes have remained healthy and that healthcare spending in orthopedics is resilient. The upcoming earnings call will provide management's perspective on these market dynamics, including procedure demand, competitive pressures, and the reimbursement landscape, offering valuable insights for anyone monitoring the medical device industry.

Innovation as the Engine for the Future

Underpinning the financial recovery and growth is Globus Medical’s relentless focus on innovation. The company launched 18 new products in 2024, setting the stage for sales momentum in 2025. Key launches that likely contributed to the year's success include the Cohere porous PEEK interbody spacer and expansions to its Modulus ALIF and orthopedic trauma systems.

The strategic acquisition of Nevro and its HFX spinal cord stimulation technology further broadened the company’s innovative offerings into the chronic pain space. Company leadership has consistently emphasized a commitment to disciplined investment in research and development and has signaled a robust pipeline of new products for 2026. As investors look beyond the 2025 numbers, the discussion around this pipeline and the sustained implant pull-through from its growing base of enabling technology will be paramount in assessing the long-term growth story for Globus Medical.